CorMedix Inc. (NASDAQ:CRMD) Shares Bought by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. raised its holdings in CorMedix Inc. (NASDAQ:CRMD) by 11.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 174,418 shares of the company’s stock after purchasing an additional 17,869 shares during the period. Charles Schwab Investment Management Inc.’s holdings in CorMedix were worth $1,413,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in CRMD. FMR LLC raised its stake in shares of CorMedix by 54.3% during the 3rd quarter. FMR LLC now owns 4,618 shares of the company’s stock worth $37,000 after buying an additional 1,625 shares during the period. Janney Montgomery Scott LLC purchased a new stake in CorMedix in the 4th quarter worth $81,000. BNP Paribas Financial Markets raised its position in CorMedix by 130.3% during the third quarter. BNP Paribas Financial Markets now owns 11,950 shares of the company’s stock worth $97,000 after acquiring an additional 6,761 shares during the period. Legato Capital Management LLC purchased a new position in CorMedix during the fourth quarter valued at $97,000. Finally, China Universal Asset Management Co. Ltd. acquired a new stake in shares of CorMedix in the fourth quarter valued at about $104,000. 34.18% of the stock is currently owned by hedge funds and other institutional investors.

CorMedix Stock Performance

Shares of CorMedix stock opened at $6.74 on Friday. The business’s 50 day moving average price is $10.43 and its 200 day moving average price is $9.91. The company has a market cap of $408.96 million, a price-to-earnings ratio of -8.32 and a beta of 1.53. CorMedix Inc. has a one year low of $3.61 and a one year high of $13.85.

CorMedix (NASDAQ:CRMD) last posted its quarterly earnings results on Tuesday, March 25th. The company reported $0.22 EPS for the quarter, topping the consensus estimate of $0.17 by $0.05. The company had revenue of $30.00 million for the quarter, compared to analysts’ expectations of $27.46 million. The company’s revenue was up 29900.0% on a year-over-year basis. On average, analysts predict that CorMedix Inc. will post -0.32 EPS for the current fiscal year.

Analyst Ratings Changes

CRMD has been the subject of several research analyst reports. Royal Bank of Canada restated an “outperform” rating and set a $12.00 price target on shares of CorMedix in a research report on Wednesday. Leerink Partners started coverage on CorMedix in a report on Friday, March 7th. They set an “outperform” rating and a $18.00 target price for the company. D. Boral Capital reaffirmed a “buy” rating and issued a $15.00 price target on shares of CorMedix in a research note on Tuesday, March 25th. Leerink Partnrs raised CorMedix to a “strong-buy” rating in a research note on Friday, March 7th. Finally, Needham & Company LLC lowered their target price on shares of CorMedix from $18.00 to $12.00 and set a “buy” rating on the stock in a research note on Wednesday. One analyst has rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, CorMedix presently has an average rating of “Moderate Buy” and an average price target of $15.14.

About CorMedix

CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.